321 related articles for article (PubMed ID: 28779511)
1. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
[TBL] [Abstract][Full Text] [Related]
2. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice.
Velazquez R; Meechoovet B; Ow A; Foley C; Shaw A; Smith B; Oddo S; Hulme C; Dunckley T
Mol Neurobiol; 2019 Dec; 56(12):8364-8375. PubMed ID: 31240602
[TBL] [Abstract][Full Text] [Related]
3. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
4. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
[TBL] [Abstract][Full Text] [Related]
5. Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.
Caccamo A; Branca C; Talboom JS; Shaw DM; Turner D; Ma L; Messina A; Huang Z; Wu J; Oddo S
J Neurosci; 2015 Oct; 35(41):14042-56. PubMed ID: 26468204
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of miR-26a-5p Suppresses Tau Phosphorylation and Aβ Accumulation in the Alzheimer's Disease Mice by Targeting DYRK1A.
Liu Y; Wang L; Xie F; Wang X; Hou Y; Wang X; Liu J
Curr Neurovasc Res; 2020; 17(3):241-248. PubMed ID: 32286945
[TBL] [Abstract][Full Text] [Related]
7. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
8. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
[TBL] [Abstract][Full Text] [Related]
9. Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7.
Chu D; Lei L; Gu S; Liu F; Wu F
Biochem Pharmacol; 2024 Jun; 224():116233. PubMed ID: 38663682
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
Souchet B; Audrain M; Billard JM; Dairou J; Fol R; Orefice NS; Tada S; Gu Y; Dufayet-Chaffaud G; Limanton E; Carreaux F; Bazureau JP; Alves S; Meijer L; Janel N; Braudeau J; Cartier N
Acta Neuropathol Commun; 2019 Mar; 7(1):46. PubMed ID: 30885273
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
Wu X; Kosaraju J; Zhou W; Tam KY
ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
[TBL] [Abstract][Full Text] [Related]
12. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.
Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA
J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868
[TBL] [Abstract][Full Text] [Related]
13. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease.
Shen Y; Hua L; Yeh CK; Shen L; Ying M; Zhang Z; Liu G; Li S; Chen S; Chen X; Yang X
Theranostics; 2020; 10(25):11794-11819. PubMed ID: 33052247
[TBL] [Abstract][Full Text] [Related]
15. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
16. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
Wu X; Kosaraju J; Zhou W; Tam KY
Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
[TBL] [Abstract][Full Text] [Related]
17. Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease.
Yang JT; Wang ZJ; Cai HY; Yuan L; Hu MM; Wu MN; Qi JS
Neurosci Bull; 2018 Oct; 34(5):736-746. PubMed ID: 30099679
[TBL] [Abstract][Full Text] [Related]
18. Alcohol drinking exacerbates neural and behavioral pathology in the 3xTg-AD mouse model of Alzheimer's disease.
Hoffman JL; Faccidomo S; Kim M; Taylor SM; Agoglia AE; May AM; Smith EN; Wong LC; Hodge CW
Int Rev Neurobiol; 2019; 148():169-230. PubMed ID: 31733664
[TBL] [Abstract][Full Text] [Related]
19. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Li JG; Praticò D
PLoS One; 2013; 8(8):e70991. PubMed ID: 23951061
[TBL] [Abstract][Full Text] [Related]
20. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
